Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells 15,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $106.82, for a total transaction of $1,602,300.00. Following the transaction, the chief executive officer now owns 435,219 shares in the company, valued at approximately $46,490,093.58. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Grant Pickering also recently made the following trade(s):

• On Monday, October 7th, Grant Pickering sold 7,098 shares of Vaxcyte stock. The shares were sold at an average price of $109.21, for a total transaction of $775,172.58.
• On Friday, August 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $78.98, for a total transaction of $1,184,700.00.

Vaxcyte Stock Performance

Shares of PCVX traded down $0.80 during mid-day trading on Monday, hitting $106.49. 549,530 shares of the company were exchanged, compared to its average volume of 829,826. Vaxcyte, Inc. has a 1-year low of $46.16 and a 1-year high of $121.06. The stock has a market cap of $11.89 billion, a price-to-earnings ratio of -22.75 and a beta of 1.01. The company has a 50 day moving average of $109.48 and a 200-day moving average of $86.36.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter in the previous year, the firm posted ($0.70) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Institutional Trading of Vaxcyte

Several large investors have recently bought and sold shares of the business. Lisanti Capital Growth LLC grew its stake in Vaxcyte by 68.1% during the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock valued at $3,715,000 after acquiring an additional 13,175 shares in the last quarter. Chartwell Investment Partners LLC grew its stake in shares of Vaxcyte by 24.1% in the 3rd quarter. Chartwell Investment Partners LLC now owns 14,146 shares of the company’s stock valued at $1,617,000 after buying an additional 2,745 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Vaxcyte in the 3rd quarter valued at approximately $1,016,000. TimesSquare Capital Management LLC purchased a new stake in shares of Vaxcyte in the 3rd quarter valued at approximately $30,752,000. Finally, Atria Investments Inc purchased a new stake in shares of Vaxcyte in the 3rd quarter valued at approximately $286,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PCVX. Bank of America increased their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Leerink Partners boosted their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Needham & Company LLC boosted their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Mizuho upped their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Finally, Jefferies Financial Group upped their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.